Loading
A phase 2 trial of KC1036 in thymoma and thymic carcinoma, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.
A Study of KC1036 in Patients with Advanced Thymic Tumors is a phase 2 interventional study registered as NCT05683886 by Beijing Konruns Pharmaceutical Co., Ltd., with 30 participants planned, started 2023-02-22 and due to reach its primary completion in 2025-02. Interventions recorded: KC1036.
Shares Beijing Konruns Pharmaceutical, KC1036 and the tag pipeline.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma and the tag pipeline.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma and the tag pipeline.
Shares Thymic carcinoma, Thymoma and thymic carcinoma and the tag pipeline.
Shares Beijing Konruns Pharmaceutical, KC1036.
Shares Beijing Konruns Pharmaceutical, KC1036.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3).